Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Reuters

Nov 10

Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Hansoh Pharmaceutical Group Co., Ltd. has announced positive Phase 2 clinical trial results for HS-20089 (also known as GSK5733584), a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented as an oral presentation at the 2025 International Gynecologic Cancer Society (IGCS) Annual Global Meeting and were previously shared at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. As of the June 20, 2025 data cutoff, HS-20089 demonstrated a confirmed objective response rate $(ORR)$ of 48.5% and a duration of response (DoR) of 6.8 months in heavily pretreated PROC patients, regardless of tumor B7-H4 expression. The median progression-free survival (mPFS) was 6.4 months and the median overall survival (mOS) was 14.6 months, with a median follow-up time of 11.5 months. The safety profile was consistent with previous studies, and no cases of interstitial lung disease were reported. A Phase 3 study is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582981074"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582981074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582981074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582981074","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive Phase 2 clinical trial results for HS-20089 (also known as GSK5733584), a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented as an oral presentation at the 2025 International Gynecologic Cancer Society (IGCS) Annual Global Meeting and were previously shared at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. As of the June 20, 2025 data cutoff, HS-20089 demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5% and a duration of response (DoR) of 6.8 months in heavily pretreated PROC patients, regardless of tumor B7-H4 expression. The median progression-free survival (mPFS) was 6.4 months and the median overall survival (mOS) was 14.6 months, with a median follow-up time of 11.5 months. The safety profile was consistent with previous studies, and no cases of interstitial lung disease were reported. A Phase 3 study is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive Phase 2 clinical trial results for HS-20089 (also known as GSK5733584), a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented as an oral presentation at the 2025 International Gynecologic Cancer Society (IGCS) Annual Global Meeting and were previously shared at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. As of the June 20, 2025 data cutoff, HS-20089 demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5% and a duration of response (DoR) of 6.8 months in heavily pretreated PROC patients, regardless of tumor B7-H4 expression. The median progression-free survival (mPFS) was 6.4 months and the median overall survival (mOS) was 14.6 months, with a median follow-up time of 11.5 months. The safety profile was consistent with previous studies, and no cases of interstitial lung disease were reported. A Phase 3 study is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9HFFTJ:1","article_id":"2582981074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582981074","pubTimestamp":1762742211,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. has announced positive Phase 2 clinical trial results for HS-20089 , a B7-H4-targeted antibody-drug conjugate , in patients with platinum-resistant ovarian cancer . The findings were presented as an oral presentation at the 2025 International Gynecologic Cancer Society  Annual Global Meeting and were previously shared at the 2025 European Society for Medical Oncology  Annual Meeting. As of the June 20, 2025 data cutoff, HS-20089 demonstrated a confirmed objective response rate  of 48.5% and a duration of response  of 6.8 months in heavily pretreated PROC patients, regardless of tumor B7-H4 expression. The median progression-free survival  was 6.4 months and the median overall survival  was 14.6 months, with a median follow-up time of 11.5 months. The safety profile was consistent with previous studies, and no cases of interstitial lung disease were reported. A Phase 3 study is ongoing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药","BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"豪森制药报告HS-20089治疗铂类耐药卵巢癌的2期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive Phase 2 clinical trial results for HS-20089 (also known as GSK5733584), a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented as an oral presentation at the 2025 International Gynecologic Cancer Society (IGCS) Annual Global Meeting and were previously shared at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. As of the June 20, 2025 data cutoff, HS-20089 demonstrated a confirmed objective response rate $(ORR)$ of 48.5% and a duration of response (DoR) of 6.8 months in heavily pretreated PROC patients, regardless of tumor B7-H4 expression. The median progression-free survival (mPFS) was 6.4 months and the median overall survival (mOS) was 14.6 months, with a median follow-up time of 11.5 months. The safety profile was consistent with previous studies, and no cases of interstitial lung disease were reported. A Phase 3 study is ongoing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}